1) BOT received a CRL - it indicated the only negatives related to NON-clinical matters - meaning, IF they have all been adequately addressed, the drug should be approved - the FDA flagged NO drug related issues in the CRL.
2) All royalties are now owned by BOT - except a master 5% royalty to the lab that first developed the drug candidate - BOT bought out all the previous commercial promoters royalties - ie, all royalties now 95% owned by BOT! A VERY Wise move!!!!
I hope BOT approval drops in the next few weeks....it should be a bit early...but that's just wild speculation on my part....but given it's all packaging/labelling/diagram issues.....fingers crossed!
- Forums
- ASX - By Stock
- BOT
- Sofdra - Post approval royalties, costs and earnings
Sofdra - Post approval royalties, costs and earnings, page-13
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BOT (ASX) to my watchlist
|
|||||
Last
38.0¢ |
Change
0.010(2.70%) |
Mkt cap ! $687.8M |
Open | High | Low | Value | Volume |
37.0¢ | 38.0¢ | 36.5¢ | $1.324M | 3.541M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 4056 | 37.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
38.0¢ | 653729 | 17 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 4056 | 0.370 |
3 | 139768 | 0.365 |
7 | 205337 | 0.360 |
2 | 94461 | 0.355 |
4 | 439000 | 0.350 |
Price($) | Vol. | No. |
---|---|---|
0.380 | 649482 | 16 |
0.385 | 410186 | 6 |
0.390 | 352859 | 19 |
0.395 | 378120 | 10 |
0.400 | 866716 | 22 |
Last trade - 16.10pm 15/08/2024 (20 minute delay) ? |
Featured News
BOT (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online